Salud financiera de hoja de balance de Bio-Gene Technology

Salud financiera controles de criterios 4/6

Bio-Gene Technology tiene un patrimonio de los accionistas total de A$2.8M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$3.2M y A$368.4K respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$2.21m
Patrimonio	AU$2.79m
Total pasivo	AU$368.45k
Activos totales	AU$3.16m

Actualizaciones recientes sobre salud financiera

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Feb 22

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Oct 25

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Jun 20

Recent updates

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Feb 22

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Oct 25

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Jun 20

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Apr 28

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Jan 11

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$2.9M) de BGT superan a sus pasivos a corto plazo (A$345.9K).

Pasivo a largo plazo: Los activos a corto plazo de BGT (A$2.9M) superan a sus pasivos a largo plazo (A$22.5K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: BGT está libre de deudas.

Reducción de la deuda: BGT no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BGT tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: BGT tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 7.5% cada año

Salud financiera de hoja de balance de Bio-Gene Technology

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Recent updates

Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024

New major risk - Share price stability

New minor risk - Financial data availability

New minor risk - Share price stability

Bio-Gene Technology Limited Approves the Election of Alex Ding as Director

Bio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFO

Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company Secretary

Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023

New minor risk - Shareholder dilution

New major risk - Financial position

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)

Bio-Gene Technology Limited Announces Managing Director Changes

New major risk - Market cap size

Bio-Gene Technology Limited Announces Changes to the Board

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)

Bio-Gene Technology Limited Submits Application to Secure Additional IP for Qcidetm

No independent directors

Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022

Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)

No independent directors

Bio-Gene Technology Limited Announces Positive Stored Grain Pest Results

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Bio-Gene Technology Limited Appoints Sarah Driessens as Head of Regulatory Affairs

Bio-Gene Technology Limited announced that it has received AUD 3.04775 million in funding

Bio-Gene Technology Limited announced that it expects to receive AUD 3.21931 million in funding

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)

Forecast to breakeven in 2024

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Bio-Gene Technology Limited Appoints James Joughin as Non-Executive Director of the Company and Chairman of Audit and Risk Committee, Effective 1 March 2021

Bio-Gene Technology Limited Announces Flavocide MoA Studies Confirm Target Site of Activity

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)

Bio-Gene Technology Limited Announces Positive Preliminary Results from Aquatic (Rainbow Trout) and Avian (Mallard Duck) Eco-Toxicity Studies

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Bio-Gene Technology Limited Appoints Peter Beetham as Non- Executive Director, Effective from 21 December 2020

Bio-Gene Technology Limited Announces Changes of Directors

Full year earnings released - AU$0.016 loss per share

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera